nach oben

Erschienen in:

13.06.2022 | Original Article

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

verfasst von: Cem Onal, Ozan Cem Guler, Pervin Hurmuz, Guler Yavas, Burak Tilki, Ezgi Oymak, Cagdas Yavas, Gokhan Ozyigit

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to analyze the prognostic factors associated with overall survival (OS) and progression-free survival (PFS) in patients with bone-only metastatic renal cell carcinoma (RCC) who have five or fewer lesions treated with stereotactic body radiotherapy (SBRT).

Methods

The clinical data of 54 patients with 70 bone metastases undergoing SBRT treated between 2013 and 2020 with a dose of at least 5 Gy per fraction and a biologically effective dose (BED) of at least 90 Gy were retrospectively evaluated.

Results

The majority of lesions were located in the spine (57.4%) and had only one metastasis (64.8%). After a median follow-up of 22.4 months, the 1‑ and 2‑year OS rates were 84.6% and 67.3%, respectively, and median OS was 43.1 months. The 1‑ and 2‑year PFS rates and median PFS were 63.0%, 38.9%, and 15.3 months, respectively. In SBRT-treated lesions, the 1‑year local control (LC) rate was 94.9%. Age, metastasis localization, and number of fractions of SBRT were significant prognostic factors for OS in univariate analysis. In multivariate analysis, patients with spinal metastasis had better OS compared to their counterparts, and patients who received single-fraction SBRT had better PFS than those who did not. No patient experienced acute or late toxicities of grade 3 or greater.

Conclusion

Despite excellent LC at the oligometastatic site treated with SBRT, disease progression was observed in nearly half of patients 13 months after metastasis-directed local therapy, particularly as distant disease progression other than the treated lesion, necessitating an effective systemic treatment to improve treatment outcomes.

Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284–291. https://doi.org/10.1016/j.ctrv.2011.06.011 CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160–166. https://doi.org/10.1016/j.bone.2010.09.008 CrossRefPubMed

Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362 CrossRefPubMed

Santini D, Procopio G, Porta C et al (2013) Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Plos One 8(12):e83026. https://doi.org/10.1371/journal.pone.0083026 CrossRefPubMedPubMedCentral

Santoni M, Conti A, Procopio G et al (2015) Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res 34:10. https://doi.org/10.1186/s13046-015-0122-0 CrossRefPubMedPubMedCentral

Kalra S, Verma J, Atkinson BJ et al (2017) Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 15(3):363–370. https://doi.org/10.1016/j.clgc.2017.01.010 CrossRefPubMed

McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577–584. https://doi.org/10.1016/j.eururo.2013.08.012 CrossRefPubMed

Dabestani S, Marconi L, Hofmann F et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561. https://doi.org/10.1016/S1470-2045(14)70235-9 CrossRefPubMed

10.

Grunwald V, Eberhardt B, al Bex A (2018) An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 15(8):511–521. https://doi.org/10.1038/s41585-018-0034-9 CrossRefPubMedPubMedCentral

11.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8 CrossRefPubMed

12.

Meyer E, Pasquier D, Bernadou G et al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG group. Eur J Cancer 98:38–47. https://doi.org/10.1016/j.ejca.2018.04.008 CrossRefPubMed

13.

Wang CJ, Christie A, Lin MH et al (2017) Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 98(1):91–100. https://doi.org/10.1016/j.ijrobp.2017.01.032 CrossRefPubMedPubMedCentral

14.

Marvaso G, Corrao G, Oneta O et al (2021) Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 23(8):1717–1726. https://doi.org/10.1007/s12094-021-02574-0 CrossRefPubMed

15.

Franzese C, Marvaso G, Francolini G et al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38(6):527–537. https://doi.org/10.1007/s10585-021-10131-w CrossRefPubMed

16.

Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519–2528 PubMed

17.

Guerrero M, Li XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49(20):4825–4835. https://doi.org/10.1088/0031-9155/49/20/012 CrossRefPubMed

18.

Song CW, Lee YJ, Griffin RJ et al (2015) Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93(1):166–172. https://doi.org/10.1016/j.ijrobp.2015.05.016 CrossRefPubMedPubMedCentral

19.

Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88(2):254–262. https://doi.org/10.1016/j.ijrobp.2013.07.022 CrossRefPubMedPubMedCentral

20.

Park HJ, Griffin RJ, Hui S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311–327. https://doi.org/10.1667/rr2773.1 CrossRefPubMed

21.

Kothari G, Foroudi F, Gill S et al (2015) Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 54(2):148–157. https://doi.org/10.3109/0284186X.2014.939298 CrossRefPubMed

22.

Ruhle A, Andratschke N, Siva S, Guckenberger M (2019) Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104–112. https://doi.org/10.1016/j.ctro.2019.04.012 CrossRefPubMedPubMedCentral

23.

Altoos B, Amini A, Yacoub M et al (2015) Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol 10:218. https://doi.org/10.1186/s13014-015-0528-z CrossRefPubMedPubMedCentral

24.

Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. https://doi.org/10.1093/annonc/mdq554 CrossRefPubMed

25.

Zaorsky NG, Lehrer EJ, Kothari G et al (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies. Eur Urol Oncol 2(5):515–523. https://doi.org/10.1016/j.euo.2019.05.007 CrossRefPubMed

26.

Zelefsky MJ, Greco C, Motzer R et al (2012) Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82(5):1744–1748. https://doi.org/10.1016/j.ijrobp.2011.02.040 CrossRefPubMed

27.

De B, Venkatesan AM, Msaouel P et al (2021) Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. https://doi.org/10.1111/bju.15541 CrossRefPubMed

28.

Zhang Y, Schoenhals J, Christie A et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105(2):367–375. https://doi.org/10.1016/j.ijrobp.2019.07.023 CrossRefPubMedPubMedCentral

29.

Ranck MC, Golden DW, Corbin KS et al (2013) Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 36(6):589–595. https://doi.org/10.1097/COC.0b013e31825d52b2 CrossRefPubMed

30.

Cheung P, Patel S, North SA et al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study. Eur Urol 80(6):693–700. https://doi.org/10.1016/j.eururo.2021.07.026 CrossRefPubMed

31.

Spencer KL, van der Velden JM, Wong E et al (2019) Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 111(10):1023–1032. https://doi.org/10.1093/jnci/djz101 CrossRefPubMedPubMedCentral

32.

Sahgal A, Larson DA, Chang EL (2008) Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71(3):652–665. https://doi.org/10.1016/j.ijrobp.2008.02.060 CrossRefPubMed

Titel: Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study
verfasst von: Cem Onal
Ozan Cem Guler
Pervin Hurmuz
Guler Yavas
Burak Tilki
Ezgi Oymak
Cagdas Yavas
Gokhan Ozyigit
Publikationsdatum: 13.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01962-x

Neu im Fachgebiet Onkologie

02.06.2023 | Akupunktur in der Naturheilkunde | Nachrichten

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Schützt Akupunktur vor Erbrechen nach Chemotherapie?

Erste Rebiopsie der Prostata negativ: ein ziemlich gutes Zeichen

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Risikostandardisierte Mortalitätsraten übertreffen als Qualitätsindikator die typischen „Mindestzahlen“ in der onkologischen Chirurgie – ein neuer Blick auf Krankenhauszentralisationen mithilfe nationaler bevölkerungsbezogener Daten

Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors

Stereotactic radiotherapy of brain metastases: clinical impact of three-dimensional SPACE imaging for 3T-MRI-based treatment planning

Correction to: Comparison of 3D and 4D Monte Carlo optimization in robotic tracking stereotactic body radiotherapy of lung cancer

Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)

Evaluation of the ability of the Brainlab Elements Cranial Distortion Correction algorithm to correct clinically relevant MRI distortions for cranial SRT

Neu im Fachgebiet Onkologie

Schützt Akupunktur vor Erbrechen nach Chemotherapie?

Erste Rebiopsie der Prostata negativ: ein ziemlich gutes Zeichen

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Update Onkologie